

# Pharmacy Prior Authorization Form

Fax completed form to: 877.974.4411 toll free, or 616.942.8206

This form applies to:  **Commercial (Traditional)**     **Commercial (Individual/Optimized)**  
 **Medicaid**

This request is:  **Urgent** (life threatening)     **Non-Urgent** (standard review)

Urgent means the standard review time may seriously jeopardize the life or health of the patient or the patient's ability to regain maximum function.

## Zykadia<sup>®</sup> (ceritinib)

### Member

Last Name: \_\_\_\_\_ First Name: \_\_\_\_\_  
 ID #: \_\_\_\_\_ DOB: \_\_\_\_\_ Gender: \_\_\_\_\_  
 Primary Care Physician: \_\_\_\_\_  
 Requesting Provider: \_\_\_\_\_ Prov. Phone: \_\_\_\_\_ Prov. Fax: \_\_\_\_\_  
 Provider Address: \_\_\_\_\_  
 Provider NPI: \_\_\_\_\_ Contact Name: \_\_\_\_\_  
 Provider Signature: \_\_\_\_\_ Date: \_\_\_\_\_

### Product Information

Drug product:  Zykadia 150 mg capsule    **Start date** (or date of next dose): \_\_\_\_\_  
 Zykadia 150 mg tablet    **Date of last dose** (if applicable): \_\_\_\_\_  
**Dosing frequency:** \_\_\_\_\_

### Oral oncology partial fill program

Each fill of Zykadia is limited to a 14 day supply at any network pharmacy. Patients are responsible for applicable deductible and copayments.

### Precertification Requirements

For this drug to be covered, the patient must have the following condition:

- Metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive
- Other – the patient's condition is: \_\_\_\_\_  
 Rationale for use: \_\_\_\_\_

### Additional information

Requests for any condition not listed as covered require evidence of current medical literature that substantiates the drug's efficacy or that recognized oncology organizations generally accept the treatment for the condition.